Perceptive Advisors LLC Has $27.71 Million Stock Holdings in Guardant Health, Inc. $GH

Perceptive Advisors LLC grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 87.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 300,000 shares of the company’s stock after purchasing an additional 140,000 shares during the quarter. Perceptive Advisors LLC’s holdings in Guardant Health were worth $27,711,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of GH. V Square Quantitative Management LLC bought a new position in shares of Guardant Health during the 4th quarter valued at $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health in the fourth quarter worth $31,000. Elyxium Wealth LLC bought a new stake in Guardant Health in the fourth quarter worth $35,000. Parallel Advisors LLC boosted its holdings in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. Finally, Ascentis Independent Advisors acquired a new position in Guardant Health during the first quarter worth $38,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling

In related news, Director Myrtle S. Potter sold 1,556 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $204,084.96. Following the completion of the transaction, the director owned 20,971 shares of the company’s stock, valued at approximately $2,750,556.36. The trade was a 6.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 708,565 shares of company stock valued at $90,556,597 in the last quarter. Insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $161.99 on Friday. The company has a market capitalization of $21.48 billion, a PE ratio of -46.42 and a beta of 1.59. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $176.58. The company’s fifty day moving average price is $143.44 and its 200 day moving average price is $113.38.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GH. Piper Sandler set a $127.00 target price on Guardant Health in a report on Thursday, May 21st. Citigroup upped their price target on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Bank of America increased their price objective on Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a report on Monday, July 6th. The Goldman Sachs Group reissued a “buy” rating and issued a $210.00 price objective on shares of Guardant Health in a research note on Friday. Finally, Sanford C. Bernstein boosted their target price on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $179.82.

Key Headlines Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue and testing growth exceeded expectations. Second-quarter revenue rose 44% year over year to $335.0 million, above the $314.2 million analyst estimate. Oncology revenue increased 38% to $219.1 million, while oncology test volume climbed 63% to approximately 104,000. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: Guardant raised its 2026 revenue guidance to $1.3 billion-$1.4 billion, compared with consensus around $1.3 billion. The outlook increase signals continued demand for the company’s cancer-screening and precision-oncology tests. Guardant Health hits 52-week high after guidance hike
• Positive Sentiment: JPMorgan raised its price target from $185 to $195 and maintained an “overweight” rating, reinforcing bullish analyst sentiment and suggesting additional potential upside. JPMorgan raises Guardant Health price target
• Neutral Sentiment: Guardant reported a second-quarter adjusted loss of $0.42 per share, compared with a $0.44 loss a year earlier. Reports differed on the consensus comparison, with one estimate showing a modest miss and another indicating a substantial beat. Guardant Health Q2 earnings report
• Negative Sentiment: Profitability remains a concern. Guardant continues to generate quarterly losses, and investor commentary is weighing whether rapidly rising revenue can offset ongoing spending and losses. Does Guardant’s Surging Revenue and Deeper Losses Reframe the Growth Thesis for GH?

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.